Protein-Based Artificial Nanosystems in Cancer Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Proteins are increasingly engineered for cancer therapy, with some like human serum albumin used clinically as drug carriers.
• Catalytic proteins (enzymes) show potential as anticancer agents or adjuvants, but face challenges like denaturation and poor cell permeability.
• Protein-based nanomedicines offer a strategy to overcome individual protein limitations.

Purpose of the Study:

• To review the progress of protein-based nanomedicines in cancer therapy.
• To highlight the design of protein-based nanosystems for drug delivery, adjuvant therapy, and direct therapeutic applications.
• To discuss how these systems leverage intrinsic protein advantages while mitigating deficiencies.

Main Methods:

• Literature review of protein-engineered biomedicine for cancer therapy.
• Analysis of protein characteristics for nanosystem design.
• Examination of current research in protein-based nanomedicine.

Main Results:

• Significant advancements in protein-engineered biomedicine for cancer treatment over the last decade.
• Successful clinical use of certain proteins (e.g., human serum albumin) as drug delivery carriers.
• Emerging potential of catalytic proteins as therapeutic agents, despite clinical application hurdles.
• Development of tailor-made protein-based nanosystems to enhance therapeutic efficacy.

Conclusions:

• Protein-based nanomedicines represent a promising frontier in cancer therapy.
• Strategic design of nanosystems can harness protein benefits while addressing limitations like stability and delivery.
• Further research in protein-based nanomedicine is crucial for advancing cancer treatment options.